Abstract: Stroke is an enormous public health problem with an imperative need for more effective therapies. In therapies for ischemic stroke, tissue plasminogen activators, antiplatelet agents and anticoagulants are used mainly for their antithrombotic effects. However, free radical scavengers, minocycline and growth factors have shown neuroprotective effects in the treatment of stroke, while antihypertensive drugs, lipid-lowering drugs and hypoglycemic drugs have shown beneficial effects for the prevention of stroke. In the present review, we evaluate the treatment and prevention of stroke in light of clinical studies and discuss new anti-stroke effects other than the main effects of drugs, focusing on optimal pharmacotherapy.
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Kikuchi, K.; Uchikado, H.; Morioka, M.; Murai, Y.; Tanaka, E. Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke. Int. J. Mol. Sci. 2012, 13, 7739-7761.
Kikuchi K, Uchikado H, Morioka M, Murai Y, Tanaka E. Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke. International Journal of Molecular Sciences. 2012; 13(6):7739-7761.
Kikuchi, Kiyoshi; Uchikado, Hisaaki; Morioka, Motohiro; Murai, Yoshinaka; Tanaka, Eiichiro. 2012. "Clinical Neuroprotective Drugs for Treatment and Prevention of Stroke." Int. J. Mol. Sci. 13, no. 6: 7739-7761.